Ensysce Biosciences (ENSC) Operating Expenses (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Operating Expenses of $4.2 million for Q3 2025, up 52.63% year-over-year from $2.8 million in Q3 2024, and up 35.63% quarter-over-quarter from $3.1 million in Q2 2025.
Ensysce Biosciences (ENSC) Operating Expenses (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Operating Expenses for 8 consecutive years, with $4.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Operating Expenses rose 52.63% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $10.6 million (down 10.86% YoY), while the FY2024 annual figure was $11.9 million, down 7.79% from the prior year.
- Operating Expenses grew to $4.2 million in Q3 2025 per ENSC's latest filing, from $3.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $18.1 million in Q3 2021 and bottomed at $774849.0 in Q1 2021.
- Historically, Operating Expenses has averaged $4.5 million across 5 years, with a median of $3.4 million in 2023.
- Annual changes were most pronounced in 2021 — Operating Expenses surged 1367.66% — and 2022, when it plunged 64.38%.
- Ensysce Biosciences' Operating Expenses stood at $3.6 million in 2021, then soared by 109.61% to $7.6 million in 2022, then plunged by 51.92% to $3.7 million in 2023, then jumped by 32.95% to $4.9 million in 2024, then fell by 13.24% to $4.2 million in 2025.
- Business Quant data shows ENSC's Operating Expenses at $4.2 million in Q3 2025, $3.1 million in Q2 2025, and $3.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Mar 31, 2025 | 3.29 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 3.14 Mn |
| Jun 30, 2023 | 2.78 Mn |
| Mar 31, 2023 | 3.35 Mn |
| Dec 31, 2022 | 7.63 Mn |
| Sep 30, 2022 | 6.44 Mn |
| Jun 30, 2022 | 7.26 Mn |
| Mar 31, 2022 | 5.41 Mn |
| Dec 31, 2021 | 3.64 Mn |
| Sep 30, 2021 | 18.09 Mn |
| Jun 30, 2021 | 857,133.00 |
| Mar 31, 2021 | 774,849.00 |
| Dec 31, 2020 | 1.51 Mn |